Positive Results for VES001 in Frontotemporal Degeneration Study
A recent Phase Ib/IIa clinical trial has shown promising results for VES001, the first oral treatment being evaluated for frontotemporal degeneration (FTD). This study revealed that VES001 led to a significant mean increase of over 95% in progranulin levels within cerebrospinal fluid (CSF) when compared to baseline measurements. Progranulin is a crucial protein, and its deficiency has been linked to the genetic form of FTD known as FTD-GRN. By addressing this deficiency, VES001 has the potential to prevent the onset of symptomatic FTD in affected individuals.
VES001 Potentially Normalizes Progranulin Levels
The topline findings indicate that VES001 effectively normalizes progranulin levels in individuals with genetically low concentrations of this essential protein. This breakthrough is especially significant given that individuals with FTD-GRN typically possess progranulin levels that are approximately half of those in the general population. The study also showed that higher doses of VES001 resulted in dose-dependent increases in progranulin levels in both plasma and CSF, confirming the drug’s efficacy.
Safety Profile of VES001
Safety and tolerability were key focuses during the three-month treatment period, and results indicated a favorable profile for VES001, with minimal adverse events reported. These findings pave the way for advancing VES001 into Phase IIb/III trials specifically targeting individuals with FTD-GRN, suggesting its potential to become a crucial treatment option for this population.
Vesper Bio’s Commitment to FTD Research
Vesper Bio ApS, a biotech company dedicated to developing innovative therapies for neurodegenerative diseases, announced these results from its SORT-IN-2 study, which involved asymptomatic carriers of mutations in the progranulin gene (GRN). The trial included six participants from the Netherlands and the UK, all of whom were asymptomatic but genetically predisposed to develop FTD. The study’s outcomes demonstrate not only the safety of VES001 but also its ability to significantly elevate progranulin levels, which is pivotal for neuronal health.
Expert Commentary on the Study
Professor Jonathan Rohrer from the University College London highlighted the groundbreaking nature of this oral therapy, noting that restoring progranulin levels to normal in asymptomatic mutation carriers offers hope for preventing the future onset of FTD symptoms. The trial involved participants receiving daily oral doses of VES001, initially starting with a lower dosage followed by an increase, and the drug was well tolerated throughout the study period.
Next Steps for Vesper Bio
Vesper Bio has also completed long-term toxicology studies of VES001 in animal models, further supporting the drug’s development. The findings from the SORT-IN-2 study, backed by the Alzheimer’s Drug Discovery Foundation and the Association for Frontotemporal Degeneration, are set to be fully reported in early 2026. Following this, Vesper plans to initiate a Phase IIb/III clinical trial to further assess the efficacy of VES001 in symptomatic FTD-GRN patients.
About Vesper Bio and Frontotemporal Degeneration
Vesper Bio is at the forefront of sortilin receptor biology and is focusing on developing small molecule-based selective sortilin inhibitors as new oral therapies for neurodegenerative and neuropsychiatric conditions. The lead candidate, VES001, aims to address progranulin deficiency, a significant contributor to genetically driven forms of FTD, specifically FTD-GRN. This condition, a form of frontotemporal lobar degeneration, primarily affects younger individuals and is often misdiagnosed as Alzheimer’s disease.
